18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      On-demand app-based rate and rhythm monitoring to manage atrial fibrillation through tele-consultations during COVID-19

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Correspondence During the coronavirus 2019 (COVID-19) pandemic, traditional face-to-face outpatient consultations in atrial fibrillation (AF) clinics were transformed into tele-consultations. Herein, we describe how we implemented a remote on-demand mobile health (mHealth) infrastructure, which was based on a mobile phone app using photoplethysmography (PPG) technology allowing rate and rhythm monitoring through tele-consultations (summarized in the figure) (see Fig. 1 ). Figure 1 On-demand app-based rate and rhythm monitoring to manage atrial fibrillation patients through tele-consultation. We asked our secretaries to call all patients 5-7 days before scheduled tele-consultations. The patients were instructed to download the FibriCheck mobile phone app (www.fibricheck.com). This app is CE marked, connected to a secured and certified cloud and validated to detect AF via PPG signals and to provides rate measures during sinus rhythm and AF[1], [2]. A manual outlining the download and registration process of the app was sent to the patient via email. After download and registration, patients activated a 7-day on-demand prescription by scanning a QR code which linked the app to a cloud accessible by the treating physician. The patients were instructed to use the app three times per day and in the case of symptoms. Between March 25 and April 1 2020, 38 patients with a planned tele-consultation for AF management in the Maastricht University Medical Centre+ were contacted (age 66 years (range 40-78), 57% female). Thirty (79%) patients agreed to use the app, six (16%) patients did not have access to a mobile phone or tablet and were therefore excluded, two (1%) patients refused to use the app. During the tele-consultation at 5-7 days after the initial patient contact, the patientś feedback was overwhelmingly positive. In total, 651 measurements were recorded and the quality of just 64 (10%) measurements was too low for automatic analysis. The FibriCheck algorithm defined 398 (61%) measurements as normal sinus rhythm, 143 (22%) as AF and 46 (7%) as sinus rhythm with extrasystoles. The average number of measurements per participant was 22. After each measurement, symptoms were assessed by the app: 77% of measurements were asymptomatic, dyspnea was present in 5%, palpitations in 2%, chest pain in 1% and in 15% other symptoms were reported. FibriCheck information was used for management of rate and rhythm control medication in patients planned for AF outpatient clinic or follow-up after AF ablation. During COVID-19, we implemented an on-demand app-based rate and rhythm monitoring to manage AF patients through tele-consultations in our AF-clinic, with fundamental key elements included. A case coordinator, in our team the secretary, is the main contact person for the patients explaining the app or in case of issues[3]. Patient engagement and education are important aspects of this intervention[4]. Clear instructions are required concerning why, how, and when to use the app. Patients were made aware of their critical role in this process and the importance of the measurements for treatment decisions. Active engagement and empowerment to undertake this self-management intervention contributed to regular use of the app. This application of mHealth is new compared to previous settings. The goal was to monitor rate and rhythm remotely just around tele-consultations to allow a better assessment of the disease state of the patient and to support in treatment decisions. This on-demand approach was regulated by a prescription to use the app for a limited predefined time period, which avoids unnecessary data-load and additional follow-up patients-contacts. The relatively low cost, convenience, and broad accessibility of the mobile phone app used in this approach allows a fast and broad implementation of the herein described mHealth infrastructure during the COVID-19 pandemic. No hardware is required which has several hygienic and logistical advantages. A potential disadvantage is that no electrocardiogram is provided. In conclusion, it is feasible to implement a novel app-based on-demand rhythm and rate monitoring infrastructure to efficiently provide tele-consultations in an AF population. Currently, we make this infrastructure widely available in numerous European centers within the TeleCheck-AF project to manage and improve AF patient care during the COVID-19 pandemic. Disclosures: None.

          Related collections

          Most cited references4

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Mobile Phone–Based Use of the Photoplethysmography Technique to Detect Atrial Fibrillation in Primary Care: Diagnostic Accuracy Study of the FibriCheck App

          Background Mobile phone apps using photoplethysmography (PPG) technology through their built-in camera are becoming an attractive alternative for atrial fibrillation (AF) screening because of their low cost, convenience, and broad accessibility. However, some important questions concerning their diagnostic accuracy remain to be answered. Objective This study tested the diagnostic accuracy of the FibriCheck AF algorithm for the detection of AF on the basis of mobile phone PPG and single-lead electrocardiography (ECG) signals. Methods A convenience sample of patients aged 65 years and above, with or without a known history of AF, was recruited from 17 primary care facilities. Patients with an active pacemaker rhythm were excluded. A PPG signal was obtained with the rear camera of an iPhone 5S. Simultaneously, a single‑lead ECG was registered using a dermal patch with a wireless connection to the same mobile phone. PPG and single-lead ECG signals were analyzed using the FibriCheck AF algorithm. At the same time, a 12‑lead ECG was obtained and interpreted offline by independent cardiologists to determine the presence of AF. Results A total of 45.7% (102/223) subjects were having AF. PPG signal quality was sufficient for analysis in 93% and single‑lead ECG quality was sufficient in 94% of the participants. After removing insufficient quality measurements, the sensitivity and specificity were 96% (95% CI 89%-99%) and 97% (95% CI 91%-99%) for the PPG signal versus 95% (95% CI 88%-98%) and 97% (95% CI 91%-99%) for the single‑lead ECG, respectively. False-positive results were mainly because of premature ectopic beats. PPG and single‑lead ECG techniques yielded adequate signal quality in 196 subjects and a similar diagnosis in 98.0% (192/196) subjects. Conclusions The FibriCheck AF algorithm can accurately detect AF on the basis of mobile phone PPG and single-lead ECG signals in a primary care convenience sample.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Atrial fibrillation screening with photo-plethysmography through a smartphone camera

            This cross-sectional study was set up to assess the feasibility of mass screening for atrial fibrillation (AF) with only the use of a smartphone. A local newspaper published an article, allowing to subscribe for a 7-day screening period to detect AF. Screening was performed through an application that uses photo-plethysmography (PPG) technology by exploiting a smartphone camera. Participants received instructions on how to perform correct measurements twice daily, with notifications pushed through the application’s software. In case of heart rhythm irregularities, raw PPG signals underwent secondary offline analysis to confirm a final diagnosis. From 12 328 readers who voluntarily signed up for screening (49 ± 14 years; 58% men), 120 446 unique PPG traces were obtained. Photo-plethysmography signal quality was adequate for analysis in 92% of cases. Possible AF was detected in 136 individuals (1.1%). They were older (P < 0.001), more frequently men (P < 0.001), and had higher body mass index (P = 0.004). In addition, participants who strictly adhered to the recommended screening frequency (i.e. twice daily) were more often diagnosed with possible AF (1.9% vs. 1.0% in individuals who did not adhere; P = 0.008). Symptoms of palpitations, confusion, and shortness of breath were more frequent in case of AF (P < 0.001). The cumulative diagnostic yield for possible AF increased from 0.4% with a single heart rhythm assessment to 1.4% with screening during the entire 7-day screening period. Mass screening for AF using only a smartphone with dedicated application based on PPG technology is feasible and attractive because of its low cost and logistic requirements.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The why, when and how to test for obstructive sleep apnea in patients with atrial fibrillation.

              Sleep apnea is associated with increased cardiovascular risk and may be important in atrial fibrillation (AF) management. It is present in up to 62% of the AF population and is highly under-recognized and underdiagnosed. Obstructive sleep apnea (OSA) is strongly associated with AF and non-randomized trials have shown that its treatment can help to reduce AF recurrences and maintain sinus rhythm. The 2016 European Society of Cardiology guidelines for the management of AF recommend that AF patients should be questioned regarding the symptoms of OSA and that OSA-treatment should be optimized to improve AF treatment results. However, strategies on how to implement OSA testing in the standard work-up of AF patients are not provided in the guidelines. Additionally, overnight OSA monitoring rather than interrogation for OSA-related clinical signs alone may be necessary to reliably identify OSA in the majority of AF patients. This review summarizes the available clinical data on OSA in AF patients, and discusses the following key questions: Why and When is testing for OSA needed in AF patients? How and Where should it be performed and coordinated? and Who should test for OSA? To implement OSA testing in a cardiology or electrophysiology clinic, we propose a multidisciplinary integrated care approach based on a chronic care model. We describe the tools, infrastructure and coordination needed to test for OSA in the standard workup of patients with symptomatic AF prior to the initiation of directed invasive or pharmacological rhythm control management.
                Bookmark

                Author and article information

                Contributors
                Journal
                Int J Cardiol Heart Vasc
                Int J Cardiol Heart Vasc
                International Journal of Cardiology. Heart & Vasculature
                Published by Elsevier B.V.
                2352-9067
                8 May 2020
                8 May 2020
                : 100533
                Affiliations
                [a ]Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, The Netherlands
                [b ]College of Nursing and Health Sciences, Flinders University, Adelaide, Australia
                [c ]Department of Cardiology, Radboud University Medical Centre, Nijmegen, the Netherlands
                [d ]Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, Australia
                Author notes
                [* ]Corresponding author at: Maastricht UMC+, Maastricht Heart+Vascular Center, 6202 AZ Maastricht. dominik.linz@ 123456mumc.nl
                Article
                S2352-9067(20)30180-9 100533
                10.1016/j.ijcha.2020.100533
                7205626
                32391412
                9cee2c80-9479-4e56-86f7-8ef290cb50d5
                © 2020 Published by Elsevier B.V.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 4 May 2020
                : 4 May 2020
                Categories
                Article

                Comments

                Comment on this article